The company plans to double its employee count in the next two years.
The future of healthcare is precision medicine—with the potential to revolutionise healthcare and move from a one-size-fits-all approach to an individualised one, precision medicine is viewed as an emblem of a new age.
LSIPR has discovered the top things you must consider when looking to protect your inventions in the US and/or Europe, plus one issue which matters wherever you are in the world.
Healthcare analytics compliance company Protenus raised $17 million in new funding, its leadership announced this week.
The Series C round was led by LTP, which focuses on investments in health IT and services companies. Also participating in the round were Kaiser Permanente Ventures, F-Prime Capital, Arthur Ventures, Lionbird and Providence Ventures.
Maryland’s flagship university hopes to forge ties with HQ2.
REGISTER NOW FOR OUR GREATLY ANTICIPATED 4TH ANNUAL REGIONAL CONFERENCE SEPTEMBER 19, 2019
Inova Center for Personalized Health, Fairfax You’re invited to spend the day with innovative entrepreneurs, professionals and industry leaders. Discover opportunities to help you navigate through a rapidly evolving modern industry & gain access to cutting edge technologies and tools.
With an FDA approval for its pricey CAR-T therapy Yescarta under its belt and more treatments in the pipeline, Gilead’s Kite Pharma was on the hunt for a new manufacturing site to fuel those hopes. The company found it in Maryland.
REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, today announced it entered into a license agreement with Pfizer Inc.
Shipping containers are continuing to prove their worth outside of transportation. From serving as a community-connecting space to an urban farm, one organization is now bringing them into education as mobile laboratories.
George Washington University just sold a portion of its royalty rights for a drug developed in its school of medicine, scoring a game-changing cash infusion it plans to reinvest in research and commercialization.
Through gene analysis, researchers have found different types of interferons in systemic lupus erythematosus (SLE) tissues and cells, such as skin and synovium. The analysis, which probed 2,000 gene expression datasets from SLE patients, specifically investigated modules of genes derived from the downstream interferon gene signature. It found enriched downstream interferon signatures that were predominately from IFNB1. These interferon signatures were higher when compared with the expression of downstream interferon signatures in kidneys with lupus nephritis, according to the study, published April 23 in Nature Communications Biology.1